Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer.

Zanotti L, Paderno A, Piazza C, Pagan E, Bignotti E, Romani C, Bandiera E, Calza S, Del Bon F, Nicolai P, Ravaggi A.

Laryngoscope. 2017 Nov;127(11):E408-E414. doi: 10.1002/lary.26797. Epub 2017 Aug 7.

PMID:
28782189
2.

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.

Zanotti L, Romani C, Tassone L, Todeschini P, Tassi RA, Bandiera E, Damia G, Ricci F, Ardighieri L, Calza S, Marchini S, Beltrame L, Tognon G, D'Incalci M, Pecorelli S, Sartori E, Odicino F, Ravaggi A, Bignotti E.

BMC Cancer. 2017 May 25;17(1):366. doi: 10.1186/s12885-017-3334-1.

3.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

4.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilg├╝var K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

5.

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines.

Bandiera E, Todeschini P, Romani C, Zanotti L, Erba E, Colmegna B, Bignotti E, Santin AD, Sartori E, Odicino FE, Pecorelli S, Tassi RA, Ravaggi A.

Oncol Lett. 2016 Oct;12(4):2493-2500. Epub 2016 Aug 16.

6.

Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.

Bignotti E, Calza S, Tassi RA, Zanotti L, Bandiera E, Sartori E, Odicino FE, Ravaggi A, Todeschini P, Romani C.

J Cell Mol Med. 2016 Dec;20(12):2341-2348. doi: 10.1111/jcmm.12927. Epub 2016 Jul 15.

7.

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.

Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.

Gynecol Oncol. 2016 May;141(2):303-311. doi: 10.1016/j.ygyno.2016.01.016. Epub 2016 Jan 19.

PMID:
26801941
8.

Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery.

Romani C, Cocco E, Bignotti E, Moratto D, Bugatti A, Todeschini P, Bandiera E, Tassi R, Zanotti L, Pecorelli S, Sartori E, Odicino FE, de Marco A, Santin AD, Ravaggi A, Mitola S.

Oncotarget. 2015 Oct 27;6(33):34617-28. doi: 10.18632/oncotarget.5315.

9.

Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues.

Romani C, Calza S, Todeschini P, Tassi RA, Zanotti L, Bandiera E, Sartori E, Pecorelli S, Ravaggi A, Santin AD, Bignotti E.

PLoS One. 2014 Dec 4;9(12):e113781. doi: 10.1371/journal.pone.0113781. eCollection 2014.

10.

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.

Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M.

Proteomics. 2015 Jan;15(2-3):365-73. doi: 10.1002/pmic.201400214.

PMID:
25311472
11.

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.

Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2013 Sep;51(9):1815-24. doi: 10.1515/cclm-2013-0151.

PMID:
24013103
12.

Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Rossi E, Donzelli C, Todeschini P, Romani C, Bandiera E, Zanotti L, Carnazza M, Quadraro F, Tognon G, Sartori E, Pecorelli S, Roque DM, Santin AD.

J Transl Med. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162.

13.

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.

Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD.

Br J Cancer. 2013 Jul 23;109(2):462-71. doi: 10.1038/bjc.2013.315. Epub 2013 Jun 27.

14.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28.

15.

Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma.

Bignotti E, Zanotti L, Calza S, Falchetti M, Lonardi S, Ravaggi A, Romani C, Todeschini P, Bandiera E, Tassi RA, Facchetti F, Sartori E, Pecorelli S, Roque DM, Santin AD.

BMC Clin Pathol. 2012 Nov 14;12:22. doi: 10.1186/1472-6890-12-22.

16.

Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.

Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, Tognon G, Ragnoli M, Romani C, Tassi RA, Caimi L, Odicino FE, Sartori E, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2012 Dec;50(12):2189-98.

PMID:
23096757
17.

Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer.

Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A.

ISRN Obstet Gynecol. 2012;2012:245756. doi: 10.5402/2012/245756. Epub 2012 Jun 26.

18.

Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2496-506. doi: 10.1158/1055-9965.EPI-11-0635. Epub 2011 Oct 25.

19.

HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.

Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, Bignotti E, Tassi RA, Tognon G, Galli C, Caimi L, Pecorelli S.

Clin Chim Acta. 2011 Jul 15;412(15-16):1447-53. doi: 10.1016/j.cca.2011.04.028. Epub 2011 Apr 30.

PMID:
21557935
20.

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S, Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F, Pecorelli S, Ravaggi A.

Br J Cancer. 2011 Apr 26;104(9):1418-25. doi: 10.1038/bjc.2011.109. Epub 2011 Apr 5.

21.

Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients.

Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD.

Eur J Cancer. 2010 Mar;46(5):944-53. doi: 10.1016/j.ejca.2009.12.019. Epub 2010 Jan 8.

PMID:
20060709
22.

Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response.

Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A.

Int J Gynecol Cancer. 2009 Aug;19(6):1015-21. doi: 10.1111/IGC.0b013e3181ab597f.

PMID:
19820362
23.

Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence.

Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD.

BMC Cancer. 2009 Jul 27;9:253. doi: 10.1186/1471-2407-9-253.

24.

Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas.

Romani C, Comper F, Bandiera E, Ravaggi A, Bignotti E, Tassi RA, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2009 Jul;201(1):70.e1-9. doi: 10.1016/j.ajog.2009.02.010. Epub 2009 May 8.

25.

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas.

Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD.

Br J Cancer. 2008 Sep 2;99(5):768-73. doi: 10.1038/sj.bjc.6604546.

26.

Claudin-7 expression in human epithelial ovarian cancer.

Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1262-71. doi: 10.1111/j.1525-1438.2008.01194.x. Epub 2008 Feb 19.

PMID:
18298564
27.

Mammaglobin B expression in human endometrial cancer.

Tassi RA, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E, Martinelli F, Bandiera E, Pecorelli S, Santin AD.

Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. Epub 2007 Nov 16.

PMID:
18021217
28.

Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.

Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S.

Clin Cancer Res. 2007 Jun 1;13(11):3339-46.

29.

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.

Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Sep;106(3):513-20. Epub 2007 May 31.

PMID:
17540437
30.

Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11.

PMID:
17346539
31.

Overexpression of mammaglobin B in epithelial ovarian carcinomas.

Tassi RA, Bignotti E, Rossi E, Falchetti M, Donzelli C, Calza S, Ravaggi A, Bandiera E, Pecorelli S, Santin AD.

Gynecol Oncol. 2007 Jun;105(3):578-85. Epub 2007 Mar 6.

PMID:
17343903
32.

Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE).

Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK, Hennings L, Comper F, Bandiera E, Pecorelli S.

Cancer. 2007 Apr 1;109(7):1312-22.

33.

Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients.

Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, Odicino FE, Ragnoli M, Donzelli C, Falchetti M, Calza S, Santin AD, Pecorelli S.

Arch Virol. 2006 Oct;151(10):1899-916. Epub 2006 May 29.

PMID:
16732494
34.

Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.

Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S.

Am J Obstet Gynecol. 2006 May;194(5):1296-302. Epub 2006 Apr 21.

PMID:
16647913
35.

Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect.

Gismondi A, Cifaldi L, Mazza C, Giliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A.

Blood. 2004 Jul 15;104(2):436-43. Epub 2004 Mar 4.

Supplemental Content

Loading ...
Support Center